E4NA Stock Overview
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Arovella Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.057 |
| Beta | 0.0045 |
| 1 Month Change | -10.38% |
| 3 Month Change | 3.83% |
| 1 Year Change | 24.18% |
| 3 Year Change | 512.90% |
| 5 Year Change | 120.94% |
| Change since IPO | -95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| E4NA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 5.0% | -2.5% | -2.6% |
| 1Y | 24.2% | -15.6% | 6.9% |
Return vs Industry: E4NA exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: E4NA exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| E4NA volatility | |
|---|---|
| E4NA Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E4NA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: E4NA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michael Baker | www.arovella.com |
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021.
Arovella Therapeutics Limited Fundamentals Summary
| E4NA fundamental statistics | |
|---|---|
| Market cap | €107.95m |
| Earnings (TTM) | -€5.24m |
| Revenue (TTM) | €1.17m |
92.3x
P/S Ratio-20.6x
P/E RatioIs E4NA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E4NA income statement (TTM) | |
|---|---|
| Revenue | AU$1.95m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.95m |
| Other Expenses | AU$10.70m |
| Earnings | -AU$8.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 100.00% |
| Net Profit Margin | -448.03% |
| Debt/Equity Ratio | 0% |
How did E4NA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arovella Therapeutics Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nidhi Singh | Edison Investment Research |
| Andrew Goodsall | MST Financial Services Pty Limited |